venous thrombosis

systematic review meta-analysis network meta-analysis

Select caval filterantithromboticsdirect antithrombinsdirect factor Xa inhibitorsdirect oral anticoagulant (DAO)heparin (UFH or LMWH)LMWHUFHfibrinolysis extented secondary preventionAll type of patientpatients with cancer--- uncoded (null)       antiagregantanticoagulantantiplateletcaval filterdirect anti-IIadirect anti-Xaextended anticoagulantextended LMWHhome treatmentidraparinuxindirect anti-XALMWHlocal fibrinolysisLow molecular weight heparinonce daily LMWHoral direct thrombin inhibitorprolonged oral VKAsubcutaneous heparinsynthetic oligosaccharidesynthetic pentasaccharidesystemic fibrinolysisVKA rosuvastatinapixabanaspirinBemiparincaval filterdabigatrandalteparinedoxabanenoxaparinfondaparinuxheparinidraparinuxlogiparinnadroparinrivaroxabanstreptokinaset-patinzaparinurokinasewarfarinximelagatran vs warfarinvs anticoagulantvs discontinuationvs LMWHvs oral anticoagulantvs placebovs placebo or controlvs antiplateletvs heparin/VKAvs twice daily LMWHvs UFH       DOAC without heparinheparin - DOAC

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (144)Recurrent thromboembolic event (109)Major bleeding (107)VTE (57)Short term haemorrhage (51)VTE during active anticoagulant treatment (39)Bleeding (34)Thrombus extension (30)VTE during follow-up after active anticoagulant treatment (21)Minor bleeding (18)fatal pulmonary embolism (18)major or clinically relevant non-major bleeding (17)non-fatal pulmonary embolism (15)recurrent VTE during treatment (13)Death related to venous thromboembolism (11)Stroke/intracerebral bleeding (early) (10)symptomatic pulmonary embolism (9)Bleeding (early) (9)puylmonary embolism (9)Mortality (early) (7)Any improvement in venous patency (early) (7)Complete clot lysis (late) (6)recurrent VTE (6)recurrent DVT (5)Long term death (5)Complete clot lysis (early) (4)any bleedings (4)Leg ulceration (late) (4)Pulmonary embolism (early) (4)Symptomatic deep-vein thrombosis (4)Post-thrombotic syndrome (late) (3)death at 3 months (3)Thrombocytopenia (3)Normal venous function (late) (2)Recurrent DVT/DVT extension (symptomatic) (2)Mortality (late) (1)asymptomatic pulmonary embolism (1)pulmonary embolism (symptomatic and asymptomatic) (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	Recurrent thromboembolic event
antithrombotics
not classified
EINSTEIN CHOICE (10mg), 2017    NCT	rivaroxaban 10mg	aspirin				-
DURAC II, 1997	VKA	control				-
WODIT DVT, 2001	VKA	control				-
WODIT PE, 2003	VKA	control				-
AUREC FVII, 2009	VKA	control				-
DACUS (Siragusa), 2008      NCT	VKA	control				-
PROLONG (Palarati), 2006      NCT	VKA	control				-
Vitotec, 2009	warfarin	control				-
ELATE, 2003	warfarin	low intensity warfarin			Risk of bias	-
AMPLIFY EXT 2.5mg, 2013	apixaban 2.5mg	placebo				-
AMPLIFY EXT 5mg, 2013	apixaban 5mg	placebo				-
WARFASA, 2012	aspirin	placebo				-
ASPIRE, 2012	aspirin	placebo				-
RESONATE, 2013	dabigatran	placebo				-
Van Gogh, 2007      NCT	idraparinux	placebo			Low risk of bias	-
PREVENT, 2003	low-intensity warfarin	placebo			Low risk of bias	-
EISNTEIN EXT, 2010	rivaroxaban 20mg	placebo				-
PADIS-PE (Couturaud), 2015      NCT	VKA	placebo			Low risk of bias	-
LAFIT, 1999	warfarin	placebo			Low risk of bias	-
Levine, 1995	warfarin	placebo				-
THRIVE 3, 2003	ximelagatran	placebo				-
REMEDY, 2013	dabigatran	warfarin				-
EINSTEIN CHOICE (20mg), 2017    NCT	rivaroxaban 20mg	aspirin				-
Boccalon, 2000	LMWH at home	UFH in hospital				negative
Chong, 2005	LMWH at home	UFH in hospital				suggesting
Daskalopoulos, 2005	LMWH at home	UFH in hospital				negative
Koopman, 1996	LMWH at home	UFH in hospital				negative
Levine, 1996	LMWH at home	UFH in hospital				negative
Ramacciotti, 2004	LMWH at home	UFH in hospital				negative
Faivre et al , 1988	Minoctoparine	unfractionated heparin				negative
apixaban
AMPLIFY-EXT 2.5mg, 2012      NCT	apixaban 2.5mg	discontinuation			Low risk of bias	suggesting
AMPLIFY-EXT 5mg, 2012      NCT	apixaban 5mg	discontinuation			Low risk of bias	suggesting
Botticelli DVT, 2008      NCT	apixaban (without LMWH)	LMWH/VKA			Exploratory	-
AMPLIFY, 2013      NCT	apixaban (without LMWH)	LMWH/VKA		DOAC without heparin	Low risk of bias	suggesting
aspirin
WARFASA, 2012    NCT	aspirin	discontinuation			Low risk of bias	suggesting
ASPIRE, 2012	aspirin	discontinuation				suggesting
Bemiparin
Kakkar, 2003	Bemiparin	warfarin			Risk of bias	negative
dabigatran
RE-MEDY, 2011      NCT	dabigatran	warfarin			Low risk of bias	suggesting
RE-SONATE, 2011    NCT	dabigatran	discontinuation			Low risk of bias	suggesting
RE-COVER, 2009      NCT	heparin/dabigatran	heparin/VKA		heparin - DOAC	Low risk of bias	suggesting
dalteparin
CLOT (Lee), 2003	extended dalteparin	standard treatment				suggesting
Das, 1996	Dalteparin	warfarin			Risk of bias	negative
Lee, 2003	Dalteparin	warfarin			Risk of bias	suggesting
Holmström, 1992	once daily dalteparin	twice daily dalteparin				negative
Partsch, 1996	once daily dalteparin	twice daily dalteparin				negative
Bratt et al , 1985	Dalteparin	unfractionated heparin				negative
Holm et al , 1986	Dalteparin	unfractionated heparin				negative
Bratt et al, 1990	Dalteparin	unfractionated heparin				negative
Lindmarker et al , 1993	Dalteparin	unfractionated heparin				negative
edoxaban
Hokusai-VTE Cancer, 2017      NCT	edoxaban	dalteparin	patients with cancer		Risk of bias	negative
enoxaparin
Veiga, 2000	Enoxaparin	acenocoumarol			Risk of bias	negative
González-Fajardo, 2008	Enoxaparin	coumarin			Risk of bias	-
Cesarone, 2003	extended enoxaparin	standard treatment				negative
Deitcher, 2006	extended enoxaparin	standard treatment				negative
Meyer, 2002	extended enoxaparin	standard treatment				negative
Pini, 1994	Enoxaparin	warfarin			Risk of bias	negative
Gonzalez-Fajardo, 1999	Enoxaparin	warfarin			Risk of bias	suggesting
Meyer, 2002	Enoxaparin	warfarin			Risk of bias	negative
Deitcher, 2003	Enoxaparin	warfarin			Risk of bias	negative
Merli, 2001	once daily enoxaparin	twice daily enoxaparin			Low risk of bias	negative
Merli (once daily vs UFH), 2001	once daily enoxaparin	UFH			Low risk of bias	negative
Simonneau et al , 1993	Enoxaparin	unfractionated heparin				negative
fondaparinux
MATISSE, 2004	fondaparinux	enoxaparin			Low risk of bias	negative
MATISSE PE, 2003	fondaparinux	heparin			Risk of bias	negative
heparin
Ott importé, 1998	heparin+warfarin	placebo			Low risk of bias	negative
Krahenbuhl, 1979	subcutaneous heparin	intravenous heparin				-
Bentley, 1980	subcutaneous heparin	intravenous heparin				suggesting
Andersson, 1982	subcutaneous heparin	intravenous heparin				-
Hull, 1986	subcutaneous heparin	intravenous heparin				negative
Doyle, 1987	subcutaneous heparin	intravenous heparin				negative
Walker, 1987	subcutaneous heparin	intravenous heparin				suggesting
Lopaciuk	subcutaneous heparin	intravenous heparin				negative
Pini, 1990	subcutaneous heparin	intravenous heparin				negative
Nielsen importé, 1994	heparin+phenprocoumon	phenylbutazone				-
idraparinux
Van Gogh (subgroup), 2011	idraparinux	standard treatment	patients with cancer		Exploratory	negative
VanGogh DVT, 2007    NCT	idraparinux (without heparin)	heparin/VKA			Exploratory	suggesting
VanGogh PE, 2007    NCT	idraparinux (without heparin)	heparin/VKA			Risk of bias	negative
logiparin
Siegbahn, 1989	once daily logiparin	twice daily logiparin				negative
nadroparin
Lopaciuk, 1999	Nadroparin	acenocoumarol			Risk of bias	negative
Lopez-Beret, 2001	Nadroparin	acenocoumarol			Risk of bias	negative
Lopez Beret, 2001	extended nadroparin	standard treatment				negative
Charbonnier, 1998	once daily nadroparin	twice daily nadroparin			Low risk of bias	negative
Collaborative European Multicentre, 1991	Nadroparin	unfractionated heparin				negative
Prandoni et al , 1992	Nadroparin	unfractionated heparin				suggesting
Lopaciuk et al , 1992	Nadroparin	unfractionated heparin				negative
rivaroxaban
SELECT D, 2018	rivaroxaban	dalteparin	patients with cancer		Risk of bias	suggesting
EINSTEIN-extension, 2009    NCT	rivaroxaban	discontinuation			Low risk of bias	suggesting
EINSTEIN (subgroup), 2014	rivaroxaban	enoxaparin	patients with cancer			suggesting
Einstein-DVT Dose-Ranging Study, 2008	rivaroxaban (without LMWH)	LMWH/VKA				-
Einstein-DVT Evaluation, 2010    NCT	rivaroxaban (without LMWH)	LMWH/VKA		DOAC without heparin	Low risk of bias	suggesting
Einstein-PE Evaluation, 2012      NCT	rivaroxaban (without LMWH)	LMWH/VKA			Risk of bias	-
rosuvastatin
VanGogh extension, 2007      NCT	idraparinux	discontinuation				suggesting
tinzaparin
Romera, 2009	Tinzaparin	acenocoumarol			Risk of bias	suggesting
Hull, 2006	extended tinzaparin	standard treatment				negative
Hull, 2002	Tinzaparin	warfarin			Risk of bias	negative
Hull et al , 1992	Tinzaparin	unfractionated heparin				suggesting
warfarin
Schulman, 1995	6 months	1.5 months				suggesting
Pinede, 2001	3-6 months	1.5-3 months				negative
Wells (subgroup), 2005	tinzaparin	dalteparin				negative
Levine, 1995	warfarin	discontinuation			Low risk of bias	suggesting
LAFIT (Kearon), 1999	warfarin	discontinuation				suggesting
Agnelli, 2001	warfarin	discontinuation				negative
Agnelli, 2003	warfarin	discontinuation				negative
PREVENT (Ridker), 2003	warfarin	discontinuation				suggesting
ELAET (Kearon), 2004	warfarin	discontinuation			Low risk of bias	negative
DURAC (Schulman), 1997	warfarin	discontinuation				suggesting
PROLONG (Palareti), 2006      NCT	warfarin	discontinuation				suggesting
ximelagatran
THRIVE III, 2003	ximelagatran	discontinuation			Low risk of bias	suggesting
Schulman (subgroup), 2003	ximelagatran	placebo	patients with cancer			-
Fiessinger , 2005	ximelagatran	LMWH/VKA			Low risk of bias	-
THRIVE I, 2003	ximelagatran (without LMWH)	LMWH/VKA				-
caval filter
caval filter
PREPIC, 1998	caval filter	no filter			Low risk of bias	suggesting
direct factor Xa inhibitors
ximelagatran
THRIVE III, 2003	ximelagatran	discontinuation			Low risk of bias	suggesting
direct oral anticoagulant (DAO)
not classified
EINSTEIN CHOICE (20mg), 2017    NCT	rivaroxaban 20mg	aspirin				-
apixaban
AMPLIFY-EXT 2.5mg, 2012      NCT	apixaban 2.5mg	discontinuation			Low risk of bias	suggesting
AMPLIFY-EXT 5mg, 2012      NCT	apixaban 5mg	discontinuation			Low risk of bias	suggesting
Botticelli DVT, 2008      NCT	apixaban (without LMWH)	LMWH/VKA			Exploratory	-
AMPLIFY, 2013      NCT	apixaban (without LMWH)	LMWH/VKA		DOAC without heparin	Low risk of bias	suggesting
dabigatran
RE-MEDY, 2011      NCT	dabigatran	warfarin			Low risk of bias	suggesting
RE-SONATE, 2011    NCT	dabigatran	discontinuation			Low risk of bias	suggesting
RE-COVER, 2009      NCT	heparin/dabigatran	heparin/VKA		heparin - DOAC	Low risk of bias	suggesting
RE-COVER II, 2011    NCT	heparin/dabigatran	heparin/VKA		heparin - DOAC	Low risk of bias	suggesting
edoxaban
Hokusai-VTE Cancer, 2017      NCT	edoxaban	dalteparin	patients with cancer		Risk of bias	negative
Edoxaban Hokusai VTE, 2013      NCT	heparin/edoxaban	heparin/VKA		heparin - DOAC	Low risk of bias	suggesting
idraparinux
Van Gogh (subgroup), 2011	idraparinux	standard treatment	patients with cancer		Exploratory	negative
rivaroxaban
SELECT D, 2018	rivaroxaban	dalteparin	patients with cancer		Risk of bias	suggesting
EINSTEIN-extension, 2009    NCT	rivaroxaban	discontinuation			Low risk of bias	suggesting
EINSTEIN (subgroup), 2014	rivaroxaban	enoxaparin	patients with cancer			suggesting
Einstein-DVT Dose-Ranging Study, 2008	rivaroxaban (without LMWH)	LMWH/VKA				-
Einstein-DVT Evaluation, 2010    NCT	rivaroxaban (without LMWH)	LMWH/VKA		DOAC without heparin	Low risk of bias	suggesting
Einstein-PE Evaluation, 2012      NCT	rivaroxaban (without LMWH)	LMWH/VKA			Risk of bias	-
rosuvastatin
VanGogh extension, 2007      NCT	idraparinux	discontinuation				suggesting
ximelagatran
THRIVE III, 2003	ximelagatran	discontinuation			Low risk of bias	suggesting
Schulman (subgroup), 2003	ximelagatran	placebo	patients with cancer			-
THRIVE I, 2003	ximelagatran (without LMWH)	LMWH/VKA				-
fibrinolysis
not classified
Kakkar (arvin), 1969	arvin	no fibrinolysis				-
heparin
Schweizer tPA, 1998	tPA+heparin	no fibrinolysis				negative
streptokinase
Arneson, 1978	streptokinase	no fibrinolysis				negative
Common, 1976	streptokinase	no fibrinolysis				negative
Elsharawy, 2002	streptokinase	no fibrinolysis				negative
Schulman, 1986	streptokinase	no fibrinolysis				negative
Tsapogas, 1973	streptokinase	no fibrinolysis				negative
Kakkar (streptokinase), 1969	streptokinase	no fibrinolysis				negative
Schweizer (systemic SK), 2000	streptokinase	no fibrinolysis				-
t-pa
Goldhaber (tPA alone), 1990	tPA	no fibrinolysis				negative
Schweizer (local tPA), 2000	tPA	no fibrinolysis				-
Turpie, 1990	tPA	no fibrinolysis			Low risk of bias	negative
Verhaeghe (high dose), 1989	tPA	no fibrinolysis			Low risk of bias	-
Goldhaber (tPA+heparin), 1990	tPA	no fibrinolysis				-
Verhaeghe (low dose), 1989	tPA	no fibrinolysis			Low risk of bias	-
urokinase
Kiil, 1981	urokinase	no fibrinolysis			Low risk of bias	negative
Schweizer (urokinase), 1998	urokinase	no fibrinolysis				negative
Schweizer (local urokinase), 2000	urokinase	no fibrinolysis				-
Schweizer (systemic urokinase), 2000	urokinase	no fibrinolysis				-
heparin (UFH or LMWH)
not classified
Boccalon, 2000	LMWH at home	UFH in hospital				negative
Chong, 2005	LMWH at home	UFH in hospital				suggesting
Daskalopoulos, 2005	LMWH at home	UFH in hospital				negative
Koopman, 1996	LMWH at home	UFH in hospital				negative
Levine, 1996	LMWH at home	UFH in hospital				negative
Ramacciotti, 2004	LMWH at home	UFH in hospital				negative
Faivre et al , 1988	Minoctoparine	unfractionated heparin				negative
Bemiparin
Kakkar, 2003	Bemiparin	warfarin			Risk of bias	negative
dalteparin
Das, 1996	Dalteparin	warfarin			Risk of bias	negative
Lee, 2003	Dalteparin	warfarin			Risk of bias	suggesting
Holmström, 1992	once daily dalteparin	twice daily dalteparin				negative
Partsch, 1996	once daily dalteparin	twice daily dalteparin				negative
Bratt et al , 1985	Dalteparin	unfractionated heparin				negative
Holm et al , 1986	Dalteparin	unfractionated heparin				negative
Bratt et al, 1990	Dalteparin	unfractionated heparin				negative
Lindmarker et al , 1993	Dalteparin	unfractionated heparin				negative
enoxaparin
Veiga, 2000	Enoxaparin	acenocoumarol			Risk of bias	negative
González-Fajardo, 2008	Enoxaparin	coumarin			Risk of bias	-
Pini, 1994	Enoxaparin	warfarin			Risk of bias	negative
Gonzalez-Fajardo, 1999	Enoxaparin	warfarin			Risk of bias	suggesting
Meyer, 2002	Enoxaparin	warfarin			Risk of bias	negative
Deitcher, 2003	Enoxaparin	warfarin			Risk of bias	negative
Merli, 2001	once daily enoxaparin	twice daily enoxaparin			Low risk of bias	negative
Merli (once daily vs UFH), 2001	once daily enoxaparin	UFH			Low risk of bias	negative
Simonneau et al , 1993	Enoxaparin	unfractionated heparin				negative
heparin
Krahenbuhl, 1979	subcutaneous heparin	intravenous heparin				-
Bentley, 1980	subcutaneous heparin	intravenous heparin				suggesting
Andersson, 1982	subcutaneous heparin	intravenous heparin				-
Hull, 1986	subcutaneous heparin	intravenous heparin				negative
Doyle, 1987	subcutaneous heparin	intravenous heparin				negative
Walker, 1987	subcutaneous heparin	intravenous heparin				suggesting
Lopaciuk	subcutaneous heparin	intravenous heparin				negative
Pini, 1990	subcutaneous heparin	intravenous heparin				negative
logiparin
Siegbahn, 1989	once daily logiparin	twice daily logiparin				negative
nadroparin
Lopaciuk, 1999	Nadroparin	acenocoumarol			Risk of bias	negative
Lopez-Beret, 2001	Nadroparin	acenocoumarol			Risk of bias	negative
Charbonnier, 1998	once daily nadroparin	twice daily nadroparin			Low risk of bias	negative
Collaborative European Multicentre, 1991	Nadroparin	unfractionated heparin				negative
Prandoni et al , 1992	Nadroparin	unfractionated heparin				suggesting
Lopaciuk et al , 1992	Nadroparin	unfractionated heparin				negative
tinzaparin
Romera, 2009	Tinzaparin	acenocoumarol			Risk of bias	suggesting
Hull, 2002	Tinzaparin	warfarin			Risk of bias	negative
Hull et al , 1992	Tinzaparin	unfractionated heparin				suggesting
warfarin
Schulman, 1995	6 months	1.5 months				suggesting
Pinede, 2001	3-6 months	1.5-3 months				negative
Levine, 1995	warfarin	discontinuation			Low risk of bias	suggesting
LAFIT (Kearon), 1999	warfarin	discontinuation				suggesting
Agnelli, 2001	warfarin	discontinuation				negative
Agnelli, 2003	warfarin	discontinuation				negative
PREVENT (Ridker), 2003	warfarin	discontinuation				suggesting
ELAET (Kearon), 2004	warfarin	discontinuation			Low risk of bias	negative
DURAC (Schulman), 1997	warfarin	discontinuation				suggesting
LMWH
not classified
Boccalon, 2000	LMWH at home	UFH in hospital				negative
Chong, 2005	LMWH at home	UFH in hospital				suggesting
Daskalopoulos, 2005	LMWH at home	UFH in hospital				negative
Koopman, 1996	LMWH at home	UFH in hospital				negative
Levine, 1996	LMWH at home	UFH in hospital				negative
Ramacciotti, 2004	LMWH at home	UFH in hospital				negative
Faivre et al , 1988	Minoctoparine	unfractionated heparin				negative
Bemiparin
Kakkar, 2003	Bemiparin	warfarin			Risk of bias	negative
dalteparin
Das, 1996	Dalteparin	warfarin			Risk of bias	negative
Lee, 2003	Dalteparin	warfarin			Risk of bias	suggesting
Holmström, 1992	once daily dalteparin	twice daily dalteparin				negative
Partsch, 1996	once daily dalteparin	twice daily dalteparin				negative
Bratt et al , 1985	Dalteparin	unfractionated heparin				negative
Holm et al , 1986	Dalteparin	unfractionated heparin				negative
Bratt et al, 1990	Dalteparin	unfractionated heparin				negative
Lindmarker et al , 1993	Dalteparin	unfractionated heparin				negative
enoxaparin
Veiga, 2000	Enoxaparin	acenocoumarol			Risk of bias	negative
González-Fajardo, 2008	Enoxaparin	coumarin			Risk of bias	-
Pini, 1994	Enoxaparin	warfarin			Risk of bias	negative
Gonzalez-Fajardo, 1999	Enoxaparin	warfarin			Risk of bias	suggesting
Meyer, 2002	Enoxaparin	warfarin			Risk of bias	negative
Deitcher, 2003	Enoxaparin	warfarin			Risk of bias	negative
Merli, 2001	once daily enoxaparin	twice daily enoxaparin			Low risk of bias	negative
Merli (once daily vs UFH), 2001	once daily enoxaparin	UFH			Low risk of bias	negative
Simonneau et al , 1993	Enoxaparin	unfractionated heparin				negative
logiparin
Siegbahn, 1989	once daily logiparin	twice daily logiparin				negative
nadroparin
Lopaciuk, 1999	Nadroparin	acenocoumarol			Risk of bias	negative
Lopez-Beret, 2001	Nadroparin	acenocoumarol			Risk of bias	negative
Charbonnier, 1998	once daily nadroparin	twice daily nadroparin			Low risk of bias	negative
Collaborative European Multicentre, 1991	Nadroparin	unfractionated heparin				negative
Prandoni et al , 1992	Nadroparin	unfractionated heparin				suggesting
Lopaciuk et al , 1992	Nadroparin	unfractionated heparin				negative
tinzaparin
Romera, 2009	Tinzaparin	acenocoumarol			Risk of bias	suggesting
Hull, 2002	Tinzaparin	warfarin			Risk of bias	negative
Hull et al , 1992	Tinzaparin	unfractionated heparin				suggesting
UFH
heparin
Krahenbuhl, 1979	subcutaneous heparin	intravenous heparin				-
Bentley, 1980	subcutaneous heparin	intravenous heparin				suggesting
Andersson, 1982	subcutaneous heparin	intravenous heparin				-
Hull, 1986	subcutaneous heparin	intravenous heparin				negative
Doyle, 1987	subcutaneous heparin	intravenous heparin				negative
Walker, 1987	subcutaneous heparin	intravenous heparin				suggesting
Lopaciuk	subcutaneous heparin	intravenous heparin				negative
Pini, 1990	subcutaneous heparin	intravenous heparin				negative